Treatment with the combination of the CD47-targeting antibody magrolimab and azacitidine induced high response rates, particularly in patients with myelodysplastic syndromes. David A. Sallman, MD, discusses findings from an ongoing phase Ib trial.
Recent Articles
A Day in the Life: Blood, Sweat, and Smears
In our newest series, hematologists working in a variety of settings provide a glimpse into their daily lives.
In this edition, Megan Nakashima, MD, peeks out...
Medical School Administrators Concerned About Insufficient Resources for Incoming Students
According to annual survey results published by the Association of American Medical Colleges (AAMC), medical school administrators are worried about a lack of training...
U.S. Officials Announce Plans for Coronavirus Vaccine
Federal officials announced on September 16 that they are planning to administer a free coronavirus vaccine to Americans within 24 hours of approval or...
FDA Releases Comparative Performance Data for COVID-19 Diagnostic Tests
To help labs, clinicians, and patients evaluate competing COVID-19 diagnostic screening products, the FDA has released performance data for more than 55 tests.
When diagnostic...
Current Issue
September 2020 Volume 6, Issue 11
This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.